Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

Bags Rights To Hypertension Therapy Zilebesiran

The Swiss major is so keen to get access to Alnylam’s RNAi therapeutic targeting angiotensinogen that it is paying $310m upfront having only seen Phase I data. Some analysts are unsure if it is a good idea.

Roche
• Source: Roche

Roche Holding AG has taken the surprising step of jumping into the cardiovascular space and teamed up with Alnylam Pharmaceuticals Inc. to co-develop and co-commercialize zilebesiran, the RNA interference (RNAi) specialist's keenly-watched twice-yearly injection for hypertension.

The Swiss giant is paying $310m upfront while Alnylam is eligible to receive additional "substantial" near-term and development milestone payments...

More from Cardiovascular

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.